Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) Relative Strength Index (RSI) is 76.04, with weekly volatility at 12.68% and ATR at 0.30. The TTPH stock’s 52-week price range has touched low of $0.56 and a $20.60 high. Intraday shares traded counted 11.73 million, which was -775.47% lower than its 30-day average trading volume of 1.34M. Its shares traded higher over the last trading session, gaining 35.22% on 05/21/20. The shares fell to a low of $2.22 before closing at $3.11. TTPH’s previous close was $2.30 while the outstanding shares total 9.27M. The firm has a beta of 1.96.
Investors have identified the Biotechnology company Tetraphase Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $12.49 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Tetraphase Pharmaceuticals Inc. (TTPH) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For TTPH, the company has in raw cash 26.15 million on their books with 0.93 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 29818000 million total, with 8144000 million as their total liabilities.
TTPH were able to record -11.15 million as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by 4.91 million. In cash movements, the company had a total of -11.15 million as operating cash flow.
Potential earnings growth for Tetraphase Pharmaceuticals Inc. (TTPH)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, Tetraphase Pharmaceuticals Inc. recorded a total of 1.75 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 27.46% coming in sequential stages and their sales for the third quarter increasing by 3.7%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 1.46 million trying to sell their products during the last quarter, with the result yielding a gross income of 0.3 million. This allows shareholders to hold on to 9.27M with the revenue now reading -1.31 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-1.63 cents a share).
Having a look at the company’s valuation, the company is expected to record -22.85 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TTPH sounds very interesting.
Is the stock of TTPH attractive?
In related news, Director, Freund John Gordon sold 14,507 shares of the company’s stock in a transaction that recorded on Dec 10. The sale was performed at an average price of 2.19, for a total value of 31,770. As the sale deal closes, the Director, Freund John Gordon now sold 524 shares of the company’s stock, valued at 1,148. Also, Director, Macdonald Guy sold 5,735 shares of the company’s stock in a deal that was recorded on Dec 06. The shares were price at an average price of 2.25 per share, with a total market value of 12,903. Following this completion of acquisition, the Director, Macdonald Guy now holds 1,870 shares of the company’s stock, valued at 4,377. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.62%.